Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study

• Helena Pla-Juher ^[2] ; Marta Pardo ^[3] ; Àngel J. Izquierdo ^[3] ; Esther Darder ^[1] ; Anna Carbó ^[2] ; Elisabet Munté ^[1] ; Sara Torres-Esquius ^[4] ; Judith Balmaña ^[4] ; Concepción Lázaro ^[1] ; Joan M. Brunet ^[2] ; Maria-Pilar Barretina-Ginesta ^[2]
  1. [1] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  2. [2] Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Girona
  3. [3] Precision Oncology Group (OncoGIR-Pro), Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona
  4. [4] Department of Medical Oncology, Vall d’Hebrón Hospital, Barcelona

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 4, 2024, págs. 1033-1037
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO).

    Methods The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry.

    Results After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93–3.95).

    Conclusions In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients.